https://diabetes.acponline.org/archives/2016/06/10/5.htm

Alert on canagliflozin and amputations

An ongoing clinical trial found an increase in leg and foot amputations, mostly affecting the toes, in patients treated with canagliflozin (Invokana, Invokamet), according to an FDA safety alert.


An ongoing clinical trial found an increase in leg and foot amputations, mostly affecting the toes, in patients treated with canagliflozin (Invokana, Invokamet), according to an FDA safety alert.

The agency continues to investigate and has not determined whether the drug increases the risk of leg and foot amputations. Clinicians should continue to follow recommendations in the drug labels and monitor patients for any new pain or tenderness, sores or ulcers, or infections in their legs or feet. They should also advise patients to seek medical advice if they experience any of these signs or symptoms.